In vivo research suggests that EPA and DHA may reduce obesity and decrease adipogenesis by overexpressing peroxisome proliferator‐activated receptor‐gamma (PPAR‐γ) and downregulating G‐protein‐coupled receptor 120 (GPR‐120) (Wei et al. 2021). Here, FFAR4 is linked to obesity disorder.